https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604171/
Esther M. Blessing, Maria M. Steenkamp, Jorge Manzanares,Charles R. Marmar.2015.
Cannabidiol as a Potential Treatment for Anxiety Disorders.12(4): 825–836. doi: 10.1007/s13311-015-0387-1
Original article: https://link.springer.com/article/10.1007%2Fs13311-015-0387-1
https://www.ncbi.nlm.nih.gov/pubmed/17157290
Costa B., Trovato A.E., Comelli F., Giagnoni G., Colleoni M. 2007. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur. J. Pharmacol.556:75–83 10.1016/j.ejphar.2006.11.006
Original article: https://www.sciencedirect.com/science/article/pii/S001429990601257X?via%3Dihub
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481531/
Alline Cristina Campos,Fabricio Araújo Moreira,Felipe Villela Gomes,Elaine Aparecida Del Bel,Francisco Silveira Guimarães.2012.
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders.367(1607): 3364–3378.
(doi: 10.1098/rstb.2011.0389)
https://www.ncbi.nlm.nih.gov/pubmed/16698671
Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S, Gallily R.2006. Cannabidiol lowers incidence of diabetes in non-obese diabetic mice.Autoimmunity.39(2):143-51 (DOI:10.1080/08916930500356674)
Original article: https://www.tandfonline.com/doi/abs/10.1080/08916930500356674?journalCode=iaut20
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707667/
Orrin Devinsky,Maria Roberta Cilio,Helen Cross,Javier Fernandez-Ruiz,Jacqueline French,Charlotte Hill,Russell Katz,
Vincenzo Di Marzo,Didier Jutras-Aswad,William George Notcutt,Jose Martinez-Orgado,Philip J. Robson,Brian G. Rohrback,Elizabeth Thiele, Benjamin Whalley,Daniel Friedman.2016.
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.doi: 10.1111/epi.12631
Original article can be found here: https://onlinelibrary.wiley.com/doi/abs/10.1111/epi.12631
https://www.ncbi.nlm.nih.gov/pubmed/27010632
Shoval G1, Shbiro L, Hershkovitz L, Hazut N, Zalsman G, Mechoulam R, Weller A.2016.
Prohedonic Effect of Cannabidiol in a Rat Model of Depression. Neuropsychobiology.73(2):123-9 (doi: 10.1159/000443890)
Original Paper: Karger: https://www.karger.com/Article/Abstract/443890
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481531
Alline Cristina Campos,Fabricio Araújo Moreira,Felipe Villela Gomes,Elaine Aparecida Del Bel,Francisco Silveira Guimarães.2012.
Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 367(1607): 3364–3378.(doi: 10.1098/rstb.2011.0389)
Original article: http://rstb.royalsocietypublishing.org/content/367/1607/3364
https://www.ncbi.nlm.nih.gov/pubmed/19442536
Izzo AA, Camilleri M. 2009.
Cannabinoids in intestinal inflammation and cancer. Pharmacol Res.60(2):117-25. (doi: 10.1016/j.phrs.2009.03.008. )
Original article: Science Direct: https://www.sciencedirect.com/science/article/abs/pii/S1043661809000838
https://www.ncbi.nlm.nih.gov/pubmed/18681481
Appendino G, Gibbons S, Giana A, Pagani A, Grassi G, Stavri M, Smith E, Rahman MM.2008.
Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. 71(8):1427-30.(doi: 10.1021/np8002673.)
Original article: Journal of Natural Products: https://pubs.acs.org/doi/abs/10.1021/np8002673
https://www.ncbi.nlm.nih.gov/pubmed/21175589
Parker LA, Rock EM, Limebeer CL. 2011.
Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol..163(7):1411-22. (doi: 10.1111/j.1476-5381.2010.01176.x.)
Original article: British Pharmalogical Society: https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/j.1476-5381.2010.01176.x
https://www.ncbi.nlm.nih.gov/pubmed/19442536
Izzo AA, Camilleri M. 2009.
Cannabinoids in intestinal inflammation and cancer. Pharmacol Res.60(2):117-25. (DOI:10.1016/j.phrs.2009.03.008)
https://www.ncbi.nlm.nih.gov/pubmed/9653194
These data suggest that anandamide blocks human breast cancer cell proliferation through CB1-like receptor-mediated inhibition of endogenous prolactin action at the level of prolactin receptor.
https://www.ncbi.nlm.nih.gov/pubmed/20090845
Remarkably, cannabinoids applied at high concentration induce apoptosis in all subclones independently of CB(1), CB(2) and AKT, but still through a mechanism involving ERK1/2.
https://www.ncbi.nlm.nih.gov/pubmed/16818650
In addition, cannabinoid treatment inhibited the spreading of pancreatic tumor cells.
https://www.ncbi.nlm.nih.gov/pubmed/21097714?dopt=Abstract
Reduced proliferation and vascularization, along with increased apoptosis, were observed in tumors obtained from animals treated with JWH-133 and Win55,212-2. Upon further elucidation into the molecular mechanism, we observed that both CB1 and CB2 agonists inhibited phosphorylation of AKT, a key signaling molecule controlling cell survival, migration, and apoptosis, and reduced matrix metalloproteinase 9 expression and activity.
https://www.ncbi.nlm.nih.gov/pubmed/19690545
Signalling pathways activated by JWH-015 included JNK (c-Jun N-terminal kinase) activation and Akt inhibition. In vivo treatment with JWH-015 caused a significant reduction in tumour growth in mice.
https://www.ncbi.nlm.nih.gov/pubmed/12511587
n cell culture experiments pharmacological activation of cannabinoid receptors induced the apoptotic death of tumorigenic epidermal cells, whereas the viability of nontransformed epidermal cells remained unaffected. Local administration of the mixed CB(1)/CB(2) agonist WIN-55,212-2 or the selective CB(2) agonist JWH-133 induced a considerable growth inhibition of malignant tumors generated by inoculation of epidermal tumor cells into nude mice. Cannabinoid-treated tumors showed an increased number of apoptotic cells.
https://www.ncbi.nlm.nih.gov/pubmed/21475304
JWH-015 reduced the growth of HCC subcutaneous xenografts, an effect that was not evident when autophagy was genetically of pharmacologically inhibited in those tumors.
Moreover, cannabinoids were also able to inhibit tumor growth and ascites in an orthotopic model of HCC xenograft. Our findings may contribute to the design of new therapeutic strategies for the management of HCC.
https://www.ncbi.nlm.nih.gov/pubmed/19047095
The effects of the CB1 agonist arachinodyl-2′-chloroethylamide and the CB2 agonist N-cyclopentyl-7-methyl-1-(2-morpholin-4-ylethyl)-1,8-naphthyridin-4(1H)-on-3-carboxamide (CB13) on tumor cell apoptosis and ceramide and tumor necrosis factor (TNF)-alpha production were evaluated.
https://www.ncbi.nlm.nih.gov/pubmed/20546877
Cell death occurred via apoptosis caused by continuous influx of calcium through TRPV2.
https://cbdinstead.com/blogs/cbd-and-mental-health/cbd-and-recovering-from-anorexia
Cell death occurred via apoptosis caused by continuous influx of calcium through TRPV2.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874292/
Additionally, there is also evidence that PCR may reduce the negative psychotropic effects, memory impairment, and appetite stimulation, anxiety and psychotic-like states of THC while enhancing its positive therapeutic actions
https://www.projectcbd.org/science/cannabis-pharmacology/cbd-and-parkinsons-disease
PCR activates a G-coupled protein receptor called “GPR6” that is highly expressed in the basal ganglia region of the brain. GPR6 is considered an “orphan receptor” because researchers have yet to find the primary endogenous compound that binds to this receptor.(1)
https://www.dementiacarecentral.com/aboutdementia/treating/cbd/#alzheimers
Memory loss and other brain deterioration indirectly leads to increased oxygen in the brain. CBD is an antioxidant, which helps reduce the problems associated with oxygen stress. Brain functions negatively impacted by oxygen stress can be improved by using CBD.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202504/
CBD, and some derivatives, were found to cause a selective anxiolytic effect in the elevated plus-maze, within a limited range of doses.
Hemp Extract Oil is 100% legal in all 50 states. Under the 2014 Farm Bill, CBD derived from Hemp Seed Oil that has less than 0.3% THC by dry weight is legal. Click the link for a copy of the farm bill HERE.
What is a farm bill? The Agricultural Act of 2014 aka the Farm Bill is an omnibus legislation passed by the United States Congress. Farm Bills are passed about every five years, creating and reauthorizing federal programs in some different interests. On February 7, 2014, President Obama signed the Farm Bill of 2013 into law. Section 7606 of the act, Legitimacy of Industrial Hemp Research, defines industrial hemp as distinct from marijuana and authorizes institutions of higher education or state department’s of agriculture in states that legalized hemp cultivation to regulate and conduct research and pilot programs. Under this law, a product of the plant can be used and processed as long as the THC (psychotropic aspect) levels are no more than 0.3%. The reason industrial hemp is so popular is it contains low TCH and high compounds of whats called Cannabinoids. Particularly one called CBD (Cannabidiol) and in many governmental studies, including the government’s patent #6630507.
Section 7606 of the 2014 US Farm Bill
The isolated Section pertaining to Industrial Hemp:
DEA Internal Directive Regarding the Presence of Cannabinoids in Products and Materials Made from the Cannabis Plant
“Products and materials that are made from the cannabis plant and which fall outside the CSA definition of marijuana (such as sterilized seeds, oil or cake made from the seeds, and mature stalks) are not controlled under the CSA. Such products may accordingly be sold and otherwise distributed throughout the United States without restriction under the CSA or its implementing regulations. The mere presence of cannabinoids is not itself dispositive as to whether a substance is within the scope of the CSA; the dispositive question is whether the substance falls within the CSA definition of marijuana.”
The World Health Organization Report
“In humans, CBD exhibits no effects indicative of any abuse or dependence potential…CBD is generally well tolerated with a good safety profile…To date, there is no evidence of recreation use of CBD or any public health related problems.”
https://hempsupporter.com/wp-content/uploads/2018/02/WHO-CBD-report.pdf
State Industrial Hemp Statutes:
http://www.ncsl.org/research/agriculture-and-rural-development/state-industrial-hemp-statutes.aspx
